Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

65992 1510824253HCLSReviewUkraineNovember2017.pdf
Energy Boardroom

Biogen/Sobi's Eloctate meets all endpoints in Kids trial

10.04.2014 / Scripintelligence

Eloctate, a long-acting Factor VIII fusion protein, was well tolerated in patients enrolled in the Phase III Kids A-LONG study. The primary endpoint of the study was to evaluate the frequency of inhibitor (neutralising antibody) development and none were…

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: